The following claims are presented for examination:

- (currently amended) A drug delivery device comprising: a drug; and a
 vascular implant having a blood-contacting surface and a helical formation on the
 blood contacting surface, the helical formation having a helix angle between
 8° and 20° and being capable of inducing helical flow to of blood flowing past
 the helical formation, and the drug being releasably associated with the helical
 formation of the vascular implant.
- (original) A drug delivery device according to claim 1 wherein the drug is mixed into the material from which the helical formation is made.
- (currently amended) A drug delivery device according to claim 1 wherein the drug is coated onto the surface of the helical formation. [[/1]]
- (currently amended) A drug delivery device according to any one of the
 preceding claim 1 wherein the helical formation is made from a polymer
 preferably a polymer foam, more preferably polyamide, polyester or
 polyurethane.

Claims 5-16 (canceled)

- (new) A drug delivery device according to claim 4 wherein the polymer is a polymer foam.
- (new) A drug delivery device according to claim 4 wherein the polymer is selected from the group consisting of: polyamide, polyester, and polyurethane.
- (new) A drug delivery device according to claim 4 wherein the drug is bound onto the cellular structure of the polymer.
- (new) A drug delivery device according to claim 1 wherein the drug is selected from the group consisting of: an anticoagulant, an antiplatelet agent, an

- angiogenesis inhibitor, a cyclooxygenase inhibitor, a gene therapy agent, and a mixture of two or more of said drugs.
- (new) A drug delivery device according to claim 1 wherein the vascular implant is selected from the group consisting of: an intravascular stent insert, a vascular graft, and a stent graft.
- (new) A drug delivery device according to claim 21 wherein the vascular implant is a stent and the drug delivery device further comprises a sleeve positioned surrounding and/or within the stent.
- (new) A drug delivery device according to claim 22 wherein the sleeve is made from expanded PTFE.
- (new) A drug delivery device according to claim 1 wherein the drug is also releasably associated with the blood-contacting surface of the vascular implant.
- 25. (new) A drug delivery device according to claim 1 wherein at least one further drug is provided releasably associated with the helical formation.
- (new) A drug delivery device according to claim 1 wherein the helix angle of the helical formation is between 8° and 20°.
- (new) A drug delivery device according to claim 1 wherein the helical formation comprises at least one fin.
- (new) A drug delivery device according to claim 27 wherein the at least one fin has the shape of a right-angle triangle in cross-section.
- (new) A drug delivery device according to claim 27 wherein the at least one fin has the shape of an isosceles triangle in cross-section.

- (new) A drug delivery device according to claim 27 where the at least one fin has the shape of a bell in cross-section.
- (new) A drug delivery device according to claim 30 where the at least one fin has the shape of an asymmetric bell in cross-section.
- (new) A drug delivery device according to claim 1 wherein the helical formation comprises a groove.